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Abstract
Rationale A significant proportion of the general popula-
tion report supplementing their diet with one or more
vitamins or minerals, with common reasons for doing so
being to combat stress and fatigue and to improve mental
functioning. Few studies have assessed the relationship
between supplementation with vitamins/minerals and psy-
chological functioning in healthy cohorts of non-elderly
adults.
Objectives The present randomised, placebo-controlled,
double–blind, parallel groups trial assessed the cognitive
and mood effects of a high-dose B-complex vitamin and
mineral supplement (Berocca®) in 215 males aged 30 to
55 years, who were in full-time employment.
Methods Participants attended the laboratory prior to and
on the last day of a 33-day treatment period where they
completed the Profile of Mood States (POMS), Perceived
Stress Scale (PSS) and General Health Questionnaire
(GHQ-12). Cognitive performance and task-related modu-
lation of mood/fatigue were assessed with the 60 min
cognitive demand battery. On the final day, participants also
completed the Stroop task for 40 min whilst engaged in
inclined treadmill walking and subsequent executive func-
tion was assessed.
Results Vitamin/mineral supplementation led to significant
improvements in ratings on the PSS, GHQ-12 and the
‘vigour’ subscale of the POMS. The vitamin/mineral group
also performed better on the Serial 3s subtractions task and
rated themselves as less ‘mentally tired’ both pre- and post-
completion of the cognitive demand battery.
Conclusions Healthy members of the general population
may benefit from augmented levels of vitamins/minerals
via direct dietary supplementation. Specifically, supplemen-
tation led to improved ratings of stress, mental health and
vigour and improved cognitive performance during intense
mental processing.
Keywords Vitamin.Mineral.Cognition.Cognitive.
Executive function.Mood.Supplementation.Deficiency.
Stress
Introduction
Optimum functioning of the central nervous system is
dependent on a wide range of micronutrients. For example,
folic acid and vitamins B12 and B6 play specific roles in
the methylation and decarboxylation processes that govern
the integrity of DNA, and the synthesis of DNA, proteins,
phospholipids and monoamine and catecholamine neuro-
transmitters (Mattson and Shea 2003). All three vitamins
also play key roles in the remethylation and metabolism of
the potentially toxic amino acid homocysteine, increased
levels of which may contribute to a range of neurodegen-
erative and psychiatric disorders via a host of deleterious
effects to cellular, haemodynamic, oxidative and vascular
parameters (Mattson and Shea 2003). Vitamin C is also the
brain’s most prevalent antioxidant and is found at its
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suggests that its one-electron donor properties make it an
essential co-factor in a plethora of processes that underlie
neural maturation, neuroprotection and neurotransmission
(Harrison and May 2009). Similarly, a number of minerals,
including zinc, magnesium and calcium, are essential for
adequate functioning of the central nervous system, and
play diverse roles including in myelination, neurotransmit-
ter synthesis and modulation of activity in the dopaminergic
and adenosinergic neurotransmitter systems (Black 1996;
Cardoso et al. 2009; Gareri et al. 1995).
There is a wealth of evidence from epidemiological
studies that clearly suggest a relationship between micro-
nutrients and psychological functioning. The largest body
of work, mainly conducted in older cohorts, has demon-
strated that circulating levels of one or more B vitamins
and/or homocysteine are related to depression (Bjelland et
al. 2003; Kim et al. 2008; Sanchez-Villegas et al. 2009;
Tiemeier et al. 2002), and cognitive performance (Durga et
al. 2006; Duthie et al. 2002; Elias et al. 2006, 2008; Feng et
al. 2006; Kado et al. 2005; Vidal et al. 2008). However, the
inter-relationship between B vitamins and homocysteine
levels and the causality of the relationships with brain
function have not yet been adequately elucidated (Elias
et al. 2006). A number of epidemiological studies
conducted in older participants have also demonstrated a
relationship between cognitive performance, or risk of
dementia, and vitamin C intake (Del Parigi et al. 2006;
E n g e l h a r te ta l .2002).
The case for direct intervention with supplements as
assessed by controlled trials is less clear. Three recently
updated Cochrane reviews examined the efficacy of vitamin
B6 (Malouf and Grimley Evans 2003); B12 (Malouf and
Sastre 2003) and B9 with or without B12 (Malouf and
Grimley Evans 2008) in attenuating the cognitive declines
associates with age and dementia. These reviews all
concluded that there is no consistent evidence for efficacy
on the basis of the small number of studies that met their
inclusion criteria. The authors recommend that further work
is needed in this area. A trial conducted by Durga et al.
(2007), cited in the latter review as being methodologically
adequate, showed that 3 years supplementation with folic
acid in 818 50- to 70-year-old participants, selected on the
basis of high homocysteine levels, led to decreased
homocysteine and improved memory function, information
processing and sensorimotor speed. The authors also note a
number of methodological concerns across the studies in
this area, including the use of insensitive instruments such
as the Mini-Mental State Exam, which may account for the
lack of consistent evidence in this area. As with B vitamins,
the evidence for direct supplementation with vitamin C in
elderly or dementia suffering cohorts is also somewhat
equivocal (Morris 2009).
In terms of supplementation with a fuller range of
vitamins and minerals, a number of studies have been
conducted in cohorts of children. Benton (2001), reviewing
the results of the effects of multi-vitamins/minerals on
children’s intelligence (IQ) across 13 studies, noted some
evidence of improved performance that was restricted to
non-verbal tests of intelligence. Following a subsequent
meta-analysis, Eilander et al. (2010) concluded, on the basis
of a non-significant trend, that there was a ‘possibility of a
small positive effect’ of supplementation on similar
measures of fluid intelligence and evidence of a significant
improvement in academic achievement from a small sub-set
of studies. A further randomised, placebo-controlled study
has also been completed after the inclusion period for these
reviews. Haskell et al. (2008) demonstrated benefits to
cognitive performance in children during 12 weeks supple-
mentation with a multi-vitamins/mineral. With regards
adults, Benton et al. (1995a, b) showed that 12 months
supplementation with a high-dose multi-vitamin was able to
improve subjective mood (Profile of Mood States—
POMS), mental health (General Health Questionnaire—
GHQ) and cognitive performance on attention tasks.
However, these effects were restricted to the females within
the sample (Benton et al. 1995a, b). Schlebusch et al.
(2000), in a placebo-controlled trial involving 300 healthy
adults, found that 4 weeks administration of a vitamin B
complex with vitamin C and minerals (Berocca Calmag®)
improved subjective ratings of stress, anxiety and psycho-
logical well-being. Similarly, Carroll et al. (2000), assessing
the effects of a similar supplement (Berocca®) in a sample
of 80 healthy males, also reported significantly attenuated
subjective stress (Perceived Stress Scale—PSS) and anxiety
(Hospital Anxiety and Depression Scale) in healthy males
following 4 weeks supplementation.
The current randomised, double-blind, placebo-
controlled, parallel groups trial therefore assessed the
effects of 33-days supplementation with a high-dose B
vitamin complex plus vitamin C and minerals (Berocca®)
on cognitive performance, mood and well-being in healthy
males in full-time employment. High levels of cognitive
demand, and the resultant mental fatigue during testing,
may provide a sensitive backdrop for the measurement of
treatment-related cognitive enhancement. Laboratory-
induced mental fatigue has also been shown to disrupt
tasks that require high levels of executive control of
cognitive processes (Kato et al. 2009; Lorist et al. 2009),
and these fatigue-related decrements may also afford a
more sensitive backdrop for assessing enhancement. This
exploratory study therefore employed a cognitive demand
battery (CDB) that elicits mental fatigue and which has
been shown to be sensitive to a number of natural
interventions (Kennedy et al. 2008; Reay et al. 2005) and
included the performance of executive function tasks during
56 Psychopharmacology (2010) 211:55–68a state of fatigue inculcated by extended cognitive task
performance and physical activity.
Materials and methods
Participants
Participants were recruited via email distribution, local
press adverts, publicity on local radio and posters in the
Newcastle upon Tyne area. Following screening and
informed consent (N=244) a total of 215 healthy males
aged 30–55 years were randomised and completed this
exploratory trial. During the blind data review process,
further five participants were removed for major protocol
violations (one non-compliance to treatment, one signifi-
cant medical condition, three body mass index (BMI)>40),
giving a per protocol sample of 210 evaluable participants
(multi-vitamin/mineral, N=103; placebo, N=107). Demo-
graphic data for each group are given in Table 1.
Screening comprised training and familiarisation with
tasks as well as ensuring participants met the inclusion
criteria of being male, aged 30–55 years and in full-time
employment and did not breech any exclusion criteria.
These included having a clinically significant medical
condition within the last 5 years, use of medication within
the previous 5 days, use of any over-the-counter vitamins
and/or other dietary supplements within the previous
4 weeks or any relevant food intolerances/sensitivity.
Information relating to demographics and baseline charac-
teristics of the two groups was also obtained at this point.
This included age, BMI and average consumption of
alcohol, cigarettes and fruit and vegetables. Consumption
levels were measured simply by self-report following
advice regarding what, according to government guidelines,
constituted a portion in the case of fruit and vegetables and
a unit in the case of alcohol.
Treatments
Participants received either placebo or a multi-vitamin/
mineral supplement (Berocca®) in identical effervescent
tablets. Participants ingested one tablet per day with water
for the 33 (±2) days of the study. The multi-vitamin/mineral
tablets contained vitamins: B1 (15 mg), B2 (15 mg), B6
(10 mg), B12 (10 mcg), C (500 mg), biotin (150 mcg), folic
acid (400 mcg), nicotinamide (50 mg) and pantothenic acid
(23 mg) and minerals: calcium (100 mg), magnesium
(100 mg) and zinc (10 mg). Participants were assigned to
treatment groups in accordance with a computer-generated
randomisation schedule provided by the manufacturer and
were dispensed the study product designated to the
corresponding randomisation number. Participants returned
all unused treatment at the final visit. Compliance (between
80% and 120% of the treatment) was assessed via tablet
counting and treatment diary cards.
Cognitive and mood measures
With the exception of the paper and pencil questionnaires
all tasks and visual analogue scales were administered
using the Computerised Mental Performance Assessment
System (COMPASS—Kennedy and Haskell under review),
a platform for the presentation of computerised tasks
derived from standard psychometric measures.
Fatigue and mood
GQH-12 (Goldberg et al. 1997) The General Health
Questionnaire is a screening instrument used for assessing
Placebo (N=107) Multi-vitamin/mineral (N=103)
Mean SD Mean SD
Age 38.8 6.35 39.7 7.08
Height 1.79 0.07 1.80 0.64
Weight 85.6 12.5 86.6 12.0
BMI 26.6 3.37 26.8 3.38
Systolic blood pressure 136 13.5 136 13.7
Diastolic blood pressure 88.0 9.66 87.6 9.51
Heart rate 71.0 11.4 70.1 12.1
Respiratory rate 16.6 4.89 16.8 6.29
Temperature 35.9 1.00 35.9 0.87
Fruit and vegetables (portions per day) 3.20 1.48 3.71 2.00
Alcohol (units per week) 15.0 10.9 13.3 11.0
Cigarettes (no. per day) 1.41 4.77 0.88 2.75
Table 1 Demographics for the
placebo and multi-vitamin/
mineral groups
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non-clinical research settings requiring repeated measure-
ments over time. The GHQ-12 consists of 12 items, each
assessing the severity of a mental problem over the past few
weeks using a 4-point scale (from 0 to 3) with higher scores
indicating worse conditions (Goldberg and Williams 1988).
PSS (Cohen et al. 1983) The PSS is a 10-item question-
naire that assesses the degree to which situations in one’s
life are appraised as stressful using a 5-point scale (0–4). It
is a widely used research instrument and its validity has
been established within a number of populations (Froelicher
et al. 2004; Golden-Kreutz et al. 2004; Mimura and
Griffiths 2004).
POMS (McNair et al. 1992) The POMS is a well-
established, factor-analytically derived measure of psycho-
logical distress for which high levels of reliability and
validity have been documented. The POMS consists of 65
adjectives rated on a 0–4 scale that can be consolidated into
‘depression-dejection’, ‘tension-anxiety’, ‘anger-hostility’,
‘confusion-bewilderment’, ‘vigour-activity’ and ‘fatigue-
inertia’ sub-scales. The latter two sub-scales can be
interpreted as measures of fatigue and have been validated
as separate factors in a number of studies. Norms have been
published for a variety of patient and non-patient groups.
Bond–Lader mood scales (Bond and Lader 1974) The
Bond and Lader scales have been utilised in numerous
pharmacological, psychopharmacological and medical tri-
als. These scales comprise a total of 16 100 mm lines
anchored at either end by antonyms (e.g., ‘alert-drowsy’,
‘calm-excited’). Participants indicate their current subjec-
tive position between the antonyms on the line. Outcomes
comprise three factor analysis derived scores: ‘Alertness’,
‘Calmness’ and ‘Contentment’.
Energy visual analogue scales Visual analogue scales
(VAS) anchored at either end by ‘very low’ and ‘very
high’ assessed the participants’ self-rated levels of ‘concen-
tration’, ‘mental stamina’ and ‘physical stamina’.V A S
anchored at either end by ‘not at all’ and ‘extremely’
assessed the participants’ self-rated fatigue levels of being
‘mentally tired’ and ‘physically tired’.
Cognitive tasks
CDB This battery is designed to assess the impact of
treatment on speed/accuracy and mental fatigue during
continuous performance of cognitively demanding tasks.
The working hypothesis underlying this approach is that
any psychoactive properties of a test substance are liable to
be more readily apparent during a period of intense
cognitive demand and the ‘mental fatigue’ state elicited by
this prolonged task performance.
In the current study, the battery performed a second role
as part of the mental component in the inculcation of
mental and physical fatigue in participants. Application of
this battery in its usual 60 min form has been shown to
reliably increase self-ratings of ‘mental fatigue’ and to be
sensitive to a number of natural interventions (Kennedy et
al. 2008; Kennedy and Scholey 2004; Reay et al. 2005).
The effects of this battery tend to increase towards the later
stages of completion. The 10-min battery (which is repeated
six times) comprises:
Serial subtractions (3s and 7s—2 min each)
The original verbal Serial 7s test has appeared in a
number of forms, including as part of the Mini-Mental State
Examination for dementia screening. In the current study
modified, 2-min computerised versions of the Serial 3s and
Serial 7s tests were utilised (Scholey et al. 2010). At the
start of each 2-min section, a standard instruction screen
informed the participant to count backwards in threes or
sevens, as quickly and accurately as possible, using the
linear number keys of the keyboard to type in each
response. Participants were also instructed verbally at the
outset that if they were to make a mistake they should carry
on subtracting from the new incorrect number. A random
starting number between 800 and 999 was presented on the
computer screen, which was cleared by the entry of the first
response. Each three-digit response was represented on
screen by an asterisk. Pressing the enter key signalled the
end of each response and cleared the three asterisks from
the screen. Performance data (number of correct subtrac-
tions and number of errors performed during the 2 min
task) were calculated for the Serial 3s and 7s elements,
separately. In the case of incorrect responses, subsequent
responses were scored as positive if they were correct in
relation to the new number.
Rapid visual information processing task (5 min)
In this task, the participant monitored a continuous series
of digits for targets of three consecutive odd or three
consecutive even digits. The digits were presented at the
rate of 100 min
−1 and the participant responded to the
detection of a target string by pressing a response key as
quickly as possible. The task was continuous and lasted for
5 min, with eight correct target strings being presented in
each minute. The task was scored for percentage of target
strings correctly detected, average reaction time for correct
detections and number of false alarms.
Subjective ‘mental fatigue’ scale
Following each repetition of the battery of tasks,
participants rated their subjective feeling of ‘mental fatigue’
via an on-screen 100-mm visual analogue scale with the
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Stroop task
Whilst performing 40 min of inclined treadmill walking
(Reebok 3-series treadmill), titrated to keep the participants
heart rate at approximately 60% of the maximum heart rate
for their age, participants performed the Stroop task. This
task was used to both inculcate further mental fatigue and
measure cognitive performance. This was a computerised
version of a commonly used classic task (Stroop 1935),
which requires attentional and central executive resources.
In this case the task ran for 40 min, with the data collapsed
into four 10-min epochs. Words describing one of four
colours (‘RED’, ‘YELLOW’, ‘GREEN’, ‘BLUE’) were
presented in different coloured fonts in the centre of a
computer screen stationed at eye level in front of the
treadmill. The participant pressed one of four coloured
response buttons mounted on the treadmill in order to
identify the font colour (e.g., if the word ‘GREEN’ was
presented in a blue font, the correct response would be to
respond with the blue button). The presented words were
either ‘congruent’ (word and font are the same colour) or
‘incongruent’ (word and font are different colours) and
were presented in a random order. The task was scored for
reaction times and accuracy of responses to ‘congruent’ and
‘incongruent’ words.
Executive functioning tasks
The following classic ‘executive’ tasks, which have been
shown to be sensitive to fatigue (van der Linden et al.
2003), were utilised.
Peg-and-ball task
In this computerised version of the original ‘Tower of
London’, executive function task participants were pre-
sented with two configurations of three coloured balls
(blue, green, red) on three pegs that held three, two and one
ball, respectively. The participants had to rearrange the balls
from the starting configuration so that they matched the
position of the balls in the goal configuration, moving one
ball that did not have a ball above it at a time. Participants
were asked to work out the entire planning sequence and
calculate the minimum number of moves required prior to
moving the balls using the mouse/cursor. Participants
completed a total of 18 trials, comprising six trials each
that could be solved in three, four and five moves,
respectively, in ascending order of difficulty. Each trial
generated scores for planning times prior to moving, time to
complete and number of moves made above the minimum
required to complete the task.
Wisconsin card sort task (Berg 1948)
This is a standard clinical measure that is commonly
used as a measure of executive functioning and is thought
to require cognitive flexibility, problem solving and the use
of feedback to guide behaviour. In this computerised
version of the test, participants were asked to match cards
that varied by colour, shape and number to four ‘key cards’.
Participants were not told how to sort the cards, but were
required to determine the correct category from the
feedback given to their responses, which changed period-
ically throughout the test. In total the current version
comprised the presentation of up to 128 cards. Overall
accuracy, percentage of perseverative and non-perseverative
errors committed and time to complete during the test were
used as the measure of executive functioning.
Procedure
Within 14 days of the initial screening visit, participants
arrived at the laboratory at 08.30 am (±30 min) for their
pre-treatment assessment (day −2). They completed an
assessment of mood and well-being comprising the GHQ-
12, the PSS, the POMS and Bond–Lader mood scales.
Immediately after this they completed the CDB for 60 min.
Fatigue was assessed immediately before and after com-
pletion of the CDB with the ‘Energy VAS’.
Participants were then dispensed their treatment for the
33 (±2)-day treatment period and instructed to take one
tablet dissolved in a full glass of water (8 oz or 250 ml of
water) every morning after waking beginning 2 days
following the laboratory visit and thereafter throughout
the study treatment period. They were also given a diary
card to record intake of tablets and any general health
observations.
Participants returned after 33 days of treatment (day 33±
2 days where necessary) and completed exactly the same
assessments. In addition to those tasks completed at baseline
(pre-treatment assessment), they also completed the Stroop
task for 40 min whilst engaged in inclined treadmill walking.
They then completed the ‘Energy VAS’ for a final time
before executive function was assessed with peg-and-ball
and Wisconsin card sort tasks. The timelines of the two
laboratory visits are shown in Fig. 1. Details of the tasks and
timelines for the final laboratory visit (day 33±2) are shown
in Fig. 2.
Statistics
Prior to analysis of the day 33 data, any baseline differences
on the performance and questionnaire measures and any
underlying cohort differences in terms of demographic and
lifestyle variables were assessed with one-way (treatment)
ANOVA.
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All total and subscale scores for the GHQ-12, PSS, POMS
and Bond–Lader questionnaires on day 33 were analysed
with one-way (treatment) ANCOVA using the respective
pre-treatment score as a covariate.
CDB scores, mental fatigue and subjective fatigue/energy
during completion
Scores for the six repetitions of the CDB and ratings on the
‘Mental Fatigue’ and the two repetitions of the ‘Energy
VAS’ (completed before and after the CDB) on day 33 were
analysed with two-way (treatment × repetition) ANCOVA
using the respective averaged pre-treatment assessment
score as a covariate.
Stroop task
Stroop scores were collapsed into four 10-minute epochs
and analysed by two-way (treatment × epoch) ANOVA.
Executive function
The peg-and-ball task and Wisconsin card sort scores and
the final ‘Energy VAS’ were analysed with one-way
(treatment) ANOVA. For those measures that included
more than one post-treatment assessment a priori planned
comparisons were made using t tests calculated with the
Mean Squares Error from the ANCOVA. In order to reduce
the potential for Type I errors only those planned
comparisons associated with a statistically significant
difference or trend (p<0.1) towards the same showing a
treatment × repetition term are reported. Given this, and the
exploratory nature of the study, the exponentially reducing
probability of significant differences occurring for one
treatment at two or more consecutive time points by
chance, and an a priori statistical analysis plan for the
study that precluded the report or interpretation of isolated
significant differences, no correction was applied for family
wise error rate across time points.
Power
A power calculation carried out a priori indicated that a
total sample size of 200 would be adequate in order to have
>80% power to detect differences between treatment groups
of moderate effect size (in accordance with Cohen 1988). Fig. 2 Testing schedule during the final laboratory visit (day 33±2 days)
Fig. 1 Timelines for the
pre-treatment (day −2) and post-
treatment (day 33±2) visits to
the laboratory
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Demographics and baseline measures
There were no significant baseline differences between the
two groups on any performance/questionnaire measures.
However, those in the multi-vitamins/minerals group
reported consuming significantly more portions of fruit/
vegetables on average per day than those in the placebo
group [F(1,208)=4.62, p<0.05]. Therefore, in addition to
pre-treatment score where applicable, fruit/vegetable intake
was included as a further covariate in the analysis of post-
treatment scores reported below. Results from ANCOVAs
both with and without ‘fruit and vegetable consumption’ as
a covariate are presented in Tables 2, 3 and 4.
Questionnaires
Treatment with multi-vitamins/minerals led to a number
of significant improvements on the questionnaire meas-
ures. Participants ratings of their general mental health
were improved in comparison to placebo, as evinced by
reduced scores on the GHQ-12 [F(1,205)=4.52, p<0.05].
Similarly they reported lower subjective stress, as mea-
sured by the PSS, in comparison to placebo [F(1,205)=
5.24, p<0.05].
Overall scores on the POMS also revealed a trend
towards improved mood that narrowly failed to reach
significance [F(1,196)=3.77, p=0.054] following multi-
vitamins/minerals compared to placebo. Reference to the
POMS sub-scales showed a significant increase in self-
reported ‘vigour’ ratings [F(1,196)=6.03, p<0.05] and a
non-significant trend [F(1,196)=3.43, p=0.07] towards
reduced ‘confusion’ levels following treatment in compar-
ison to placebo.
Unadjusted mean scores (plus SDs) and F scores from
the ANCOVAS for the above measures are presented in
Table 2. The adjusted means for those measures that
showed significant effects, or trends towards the same, are
presented graphically in Fig. 3.
Table 2 Pre- and post-treatment (day 33±2) questionnaire mood scores
Instrument Subscale N Pre-treatment
(day −2)
Post-treatment
(day33)
ANCOVA
a ANCOVA
b + fruit/veg
covariate
Fp F p
GHQ Placebo 107 9.86 3.37 9.14 3.70 3.63 0.06 4.50 <0.05
Vitamin/mineral 102 9.99 3.62 8.30 3.61
PSS Placebo 107 13.0 5.25 12.9 5.54 4.07 <0.05 5.20 <0.05
Vitamin/mineral 102 14.2 6.09 12.4 4.95
POMS Tension Placebo 100 16.0 4.58 15.8 4.95 0.10 – 0.16 –
Vitamin/mineral 100 17.2 5.90 16.3 5.23
Depression Placebo 100 21.7 7.52 21.9 8.04 2.06 – 2.1 –
Vitamin/mineral 100 22.4 8.45 21.1 7.12
Anger Placebo 100 19.5 6.41 20.0 6.53 1.36 – 1.77 –
Vitamin/mineral 100 20.3 7.47 19.6 6.35
Vigour Placebo 100 24.7 5.63 25.2 5.60 6.18 <0.05 6.00 <0.05
Vitamin/mineral 100 24.0 5.14 26.3 5.29
Fatigue Placebo 100 14.5 5.01 14.3 6.12 1.62 – 2.10 –
Vitamin/mineral 100 15.5 5.75 14.1 5.59
Confusion Placebo 100 12.9 3.78 12.9 3.98 3.26 0.07 3.40 0.07
Vitamin/mineral 100 13.8 4.13 12.7 3.97
Total Score Placebo 100 60.2 26.6 59.7 28.0 3.37 0.07 3.77 0.05
Vitamin/mineral 100 65.0 30.7 57.4 27.3
Bond–Lader Alert Placebo 105 62.9 12.6 66.4 13.9 1.12 – 1.12 –
Vitamin/mineral 98 61.4 12.6 67.1 14.6
Content Placebo 105 66.0 13.1 68.6 14.3 0.92 – 0.92 –
Vitamin/mineral 98 63.9 12.9 68.4 14.5
Calm Placebo 105 62.2 12.5 65.7 14.4 0.30 – 0.30 –
Vitamin/mineral 98 60.4 13.0 63.3 15.3
Data are mean unadjusted scores plus standard deviations, with F scores and probabilities from a one-way ANCOVA of day 33 data using pre-
treatment (day −2) scores as a covariate and with and without ‘fruit/vegetable’ consumption as an additional covariate
aANCOVA including pre-treatment baseline data as a covariate
bANCOVA including additional fruit/vegetable consumption covariate
Psychopharmacology (2010) 211:55–68 61CDB scores and changes in fatigue/energy
during completion
Performance of the CDB tasks was also improved in the
multi-vitamins/minerals group, with a significant main
effect of treatment [F(1,199)=4.05, p<0.05] showing that
participants made significantly more correct Serial 3s
subtractions in comparison to placebo across the six
repetitions of the tasks. There was also a trend towards a
treatment × repetition interaction on the number of correct
Serial 7s subtractions [F(1,199)=1.93, p=0.09]. Reference
to the planned comparisons revealed that participants made
significantly more correct responses following the first
repetition of the task [t(995)=3.53, p<0.0005], with a trend
towards the same during the second repetition [t(995)=
1.73, p=0.08]. There were no effects on the number of
errors. There were no interpretable effects on rapid visual
information processing.
In terms of the effects of task completion on ratings of
mental fatigue, there was a trend towards a beneficial
treatment related main effect on ratings of ‘mental fatigue’
across repetitions of the CDB [F(1,198)=2.90, p=0.09] in
comparison to the placebo group. There was also a main
effect of treatment on the ‘Energy VAS’ ratings of ‘mental
tiredness’ made before and after the CDB [F(1,198)=4.90,
p<0.05] with those in the multi-vitamins/minerals group
reporting lower levels of ‘mental tiredness’ than those in
the placebo group across both ratings.
Unadjusted mean scores (plus SDs) from the CDB,
including F scores from the ANCOVAS, are presented in
Table 3 with data from the pre- and post-CDB completion
of the ‘energy VAS’ presented in Table 4. The adjusted
means for those measures that showed significant effects, or
trends towards the same, are presented graphically in Fig. 4.
Stroop and executive tasks
There were no significant effects of treatment on perfor-
mance of the Stroop, peg-and-ball or WCS tasks. Nor was
the final ‘Energy VAS’, completed following all tasks,
significantly modulated.
Discussion
The current study demonstrates that 33 days supplementa-
tion with a B complex, vitamin C and minerals product
(Berocca®) benefited healthy males in terms of significant-
ly improved ratings of general mental health (GHQ-12),
reduced subjective stress (PSS) and increased ratings of
‘vigour’ (POMS), with a strong trend towards an overall
improvement in mood as assessed by the POMS. Task
performance, in terms of the number of correct Serial 3s
subtractions throughout the six repetitions of the CDB
tasks, and Serial 7s during the first repetition, was also
improved. This was accompanied by reduced ratings of
‘mental tiredness’ during CDB task performance and a
trend towards reduced ‘mental fatigue’. The analysis
omitting ‘fruit and vegetable’ consumption as a covariate
showed a similar pattern, albeit with slightly weaker results
on the GHQ-12 and POMS measures (see Tables 2, 3 and
4). Prior to treatment, there were no significant differences
between the placebo and multi-vitamin/minerals groups in
performance or ratings for any of the study outcomes.
The results presented here with regards the general
mental health and mood questionnaires directly confirm
previous findings in cohorts of healthy adults administered
the same or similar supplement. Specifically, Schlebusch et
al. (2000) found that 28 days supplementation led to
decreased anxiety, improved well-being and decreased
stress in both men and women and Carroll et al. (2000)
found that the same period of administration led, amongst
other effects, to lower GHQ scores and decreased ratings of
stress as assessed by the PSS in a sample of males. The
results are also broadly in line with those seen following
supplementation with multiple vitamins for a longer time
period (12 months) by Benton et al. (1995a), with the
exception that significant benefits to mood were seen only
in the females within their sample of 129 healthy adults.
However, it may be relevant that in this previous study only
vitamins were administered, but at very high doses, and the
sample employed was somewhat smaller than the current
study.
The benefits to task performance were largely restricted
here to an increase in correct subtractions across repetitions
on the Serial 3s task following vitamins/minerals, with a
similar effect seen only on the very first repetition of the
Serial 7s task. This differential treatment related enhance-
ment of the two tasks has been seen previously (e.g., Reay
et al. 2005; Scholey et al. 2009) and has been interpreted as
reflecting the differing cognitive demands of the two tasks.
In the case of the easier, and therefore faster, Serial 3s task,
successful completion requires resources in terms of
psychomotor function, attention, working memory and
modest amounts of executive function. However, the Serial
7s task is subjectively more difficult, has little reliance on
psychomotor speed (as response rates are approximately
halved), requires a similar amount of working memory but
entails the recruitment of much greater attentional and
executive resources. It is interesting to note that the
improvements in mental arithmetic tasks that require
attentional and executive resources are broadly in line with
improved performance seen in adult females on two
executive tasks (mental arithmetic and Stroop) within a
multi-tasking battery following 9 weeks supplementation
with multi-vitamins/minerals (Haskell et al. under review).
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Psychopharmacology (2010) 211:55–68 63Overall, the underlying rationale for the choice of
cognitive tasks employed in the study was that both the
high cognitive demands of performing the difficult CDB
battery tasks for 60 min and the general declines in
executive task performance and increased mental fatigue
that can be observed following extended cognitive task
performance in the laboratory (Kato et al. 2009; Lorist et al.
2009) would provide a more sensitive paradigm for
detecting treatment related effects. Whilst the improved
performance on the Serial 3s task suggested that this may
have been the case for the CDB portion of the assessment,
there were no treatment related improvements seen during
either the Stroop task or in performance of the two
executive function tasks at the end of the assessment.
Recent Food Standards Agency surveys of the UK
population show that small percentages of this and all
other age/gender groups suffer biochemical deficiencies
with regards each of the vitamins administered in the
current study (Ruston et al. 2004), with a bias towards
poorer micronutrient status in lower socio-economic status
groups (Nelson et al. 2007). The sample employed here
were healthy males in full-time employment. Evidence also
suggests that those who participate in research tend to be
better educated and more affluent than those who do not
participate in research (Stopponi et al. 2009). Whilst no
reference was made to any nutritional parameter as an
inclusion factor and no direct analyte data was collected,
the assumption was made here that the sample enjoyed
typical nutritional status. However, the very fact of being
able to improve mood, ratings of mental health and vigour
and aspects of task performance by simple supplementation
with B vitamins, Vitamin C and minerals indicates that the
cohort must have been suffering from less than optimal
micronutrient status at the outset. However, it is important
to note that the pre-treatment scores and ratings on all of the
measures employed in the study were equivalent between
groups, suggesting that the results are not predicated on any
pre-treatment differences in nutritional status between
groups. Given that physiological levels of vitamin analytes
were not established for practical reasons, the adequacy of
the nutritional status of the cohort and whether the results
seen here represent alleviation of deficiencies as currently
defined or whether the current definitions of deficiency
leave further room for functional improvement is something
of a moot point. Overall, these results suggest that
improving nutritional status, by supplementation if neces-
sary, may be beneficial to males within the general
population as a whole.
Interestingly, a recent study undertaken in a similar,
unselected (on a nutritional basis) cohort of females who
were administered a wider range of vitamins and minerals
for 9 weeks demonstrated improved multi-tasking and
reduced tiredness (Haskell et al. under review). In that
study a sub-section of participants also volunteered to give
blood samples and significant reductions in the blood levels
of homocysteine were seen following supplementation in
comparison to the placebo group. Whilst the relevance and
causal effect of increased homocysteine levels with regards
decrements in brain function have yet to be fully delineated
(Elias et al. 2006), the changes seen in this potentially
Table 4 Pre- and post- (day 33±2) energy VAS ratings pre- and post-completion of the CDB
Pre-treatment (day−2) Post-treatment (day33) Term ANCOVA
a ANCOVA
b + fruit/
veg covariate
N 1st
Assessment
2nd
Assessment
1st
Assessment
2nd
Assessment
Concentration Placebo 105 61.9 15.0 47.6 20.7 62.8 16.3 48.3 20.7 Cond 1.29 – 1.40 –
Vitamin/mineral 97 58.7 15.4 46.7 21.1 63.6 14.7 48.7 19.9 Cond × Ass 0.00 – 0.00 –
Mental Stamina Placebo 105 60.4 15.2 42.8 17.6 61.5 16.2 44.4 21.0 Cond 1.16 – 1.28 –
Vitamin/mineral 97 57.4 15.9 44.4 19.6 61.7 16.8 47.0 18.5 Cond × Ass 0.91 – 0.97 –
Physical Stamina Placebo 105 63.0 16.4 55.6 18.8 65.2 17.4 56.8 18.9 Cond 0.00 – 0.01 –
Vitamin/mineral 97 59.4 16.9 55.8 19.1 62.9 17.8 56.9 19.4 Cond × Ass 1.49 – 1.29 –
Mental Tiredness Placebo 105 38.9 17.7 60.5 21.4 39.3 20.6 60.6 20.1 Cond 5.18 <0.05 4.90 <0.05
Vitamin/mineral 97 42.1 20.3 62.4 18.6 35.0 20.7 58.8 20.7 Cond × Ass 0.60 – 0.59 –
Physical Tiredness Placebo 105 36.7 19.7 44.1 19.8 34.1 19.0 41.7 20.9 Cond 0.34 – 0.46 –
Vitamin/mineral 97 38.7 19.8 44.7 19.8 37.0 22.2 42.9 21.9 Cond × Ass 0.47 – 0.22 –
Data are mean unadjusted scores plus standard deviations, with F scores and probabilities from a two-way ANCOVA of day 33 data (treatment ×
repetition) using pre-treatment (day −2) scores as a covariate and with and without ‘fruit/vegetable’ consumption as an additional covariate
Cond condition, Ass assessment
aANCOVA including pre-treatment baseline data as a covariate
bANCOVA including additional fruit/vegetable consumption covariate
64 Psychopharmacology (2010) 211:55–68important physiological parameter also suggest less than
optimal micronutrient status in a similar cohort of females.
Naturally, given the multiple components of the supple-
ment administered here it is not possible to identify the
specific component(s) or physiological mechanism(s) un-
derlying the beneficial effects. Whilst, a reduction in
homocysteine is plausible, the B vitamins also contribute
to the integrity and synthesis of monoamine and catechol-
amine neurotransmitters, DNA, proteins, and phospholipids
via their roles in decarboxylation and methylation processes
(Mattson and Shea 2003). Vitamin C is the brain’s most
prevalent antioxidant and is found at its greatest concen-
trations in neuron rich areas. Its one-electron donor
properties also make it an essential co-factor in a plethora
of neural maturation, neuroprotection and neurotransmis-
sion processes relevant to brain function including as a
modulator of cholinergic, GABAergic, dopaminergic and
glutamatergic activity (Harrison and May 2009). Vitamin C
was also included here at a dose (500 mg) that approx-
imates to the intake necessary to fully saturate plasma and
circulating cells in healthy adults (Levine et al. 2001) but
which is far in excess of the recommended daily allowance
of 60 mg (which is based on the levels necessary to prevent
deficiency diseases).
Similarly the minerals zinc, magnesium and calcium
have been highlighted as those most relevant to cognitive
Fig. 3 Significant effects of multi-vitamins/minerals on ratings of
general psychological health (GHQ-12), stress (PSS) and mood
(POMS). Data shown are adjusted means from one-way ANCOVAS
of day 33 data including pre-treatment scores and fruit/vegetable
consumption as covariates. Reduced scores on the measures equate to
benefits, with the exception of ‘POMS vigour’ (*p<0.05, tp <0.1)
Psychopharmacology (2010) 211:55–68 65performance (Huskisson et al. 2007). Numerous nerve
processes depend on calcium (Gareri et al. 1995) and it is
a universal messenger of extracellular signals in a number
of cells (Rasmussen 1986a, b). Magnesium plays an
important role in a variety of metabolic reactions, particu-
larly energy-requiring processes (Ryan 1991), and has been
implicated in ensuring capacity for increased energy
expenditure (Lukaski 2000). Zinc is essential to the
structure and function of proteins and is highly concentrat-
ed in synaptic vesicles of a sub-set of glutamatergic
neurons, which are particularly prevalent in the fore-brain
(Frederickson et al. 2000). Neuropsychological impairment
has also been highlighted as one of the major health
consequences of zinc deficiency (Sandstead 2000).
The lack of data confirming pre-treatment dietary habits
and circulating levels of the relevant vitamins/minerals is a
limitation of the study and reduces the range of interpre-
tations of the results. However, it is important to note that
the two treatment groups did not differ in terms of cognitive
task performance or their ratings on the various psycho-
metric instruments employed in the study before treatment
commenced, and given the randomised methodology and
sample size, it seems reasonable to attribute the benefits
seen across a number of measures in the multi-vitamin/
mineral group to the treatment administered. Interestingly
the groups did differ significantly on their self-reported
consumption of fruit and vegetables (as per current
definitions of ‘portions’). However, this reflected greater
consumption in the vitamins/minerals group. If this factor
had any significant impact on the results, it might be
conceived as reducing the liability of finding a positive
result. The fact that including fruit/vegetable consumption
as a second covariate marginally strengthens the results on
two of the psychometric questionnaire measures, but does
not modify the general tenor of the results, suggests that
this factor may have a slight influence on the results seen
here. However, it should be noted that there was no
interpretable statistical relationship between this factor and
scores on any measures pre-treatment across groups.
A further potential limitation of this study is that the
consumption of vitamin B2 at the levels administered here
can lead to discolouration of urine due to excretion of any
excess. This could potentially have led to loss of blind in the
current study. However, all participants (both those in the
placebo group and the multi-vitamin/mineral group) were
informed that ingestion of the investigational substance
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Fig. 4 Significant effects of multi-vitamins/minerals on performance
of the cognitive demand battery tasks, ratings of ‘mental fatigue’
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and after the battery. Data shown are adjusted means from two-way
ANCOVAS (treatment × repetition) of day 33 data including averaged
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66 Psychopharmacology (2010) 211:55–68could lead to a slight yellowish discolouration of urine and
that this was harmless. No information was given that might
indicate that this phenomena would be linked solely to the
active treatment. Participants were also instructed to record
and report any health observations/changes throughout the
study period, and from a total of 210 participants, only 19
reported discolouration of urine, with four of these in the
placebo group (Chi-square, non-significant). This is in
keeping with previous findings (Carroll et al. 2000) and
suggests that the participants remained blind to treatment
condition throughout the trial.
In general, few studies have assessed the cognitive
performance effects of vitamins/minerals in healthy, non-
elderly cohorts. Whilst the merits of investigating focussed
interventions in populations at risk of disease or age-related
decrements in nutritional status and physiological parame-
ters are obvious, a good case can also be made for
conducting research with multiple micronutrients delivered
in the combinations that healthy end consumers are likely
to purchase in their everyday lives. Taken together with
previous results showing beneficial effects of vitamin/
mineral supplementation in healthy children (for reviews
see Benton 2001; Eilander et al. 2010) and adults (Benton
et al. 1995b; Carroll et al. 2000; Schlebusch et al. 2000),
these findings further suggest that augmenting vitamin/
mineral levels in healthy, normal populations may provide
beneficial effects in terms of brain function. It is unclear
whether these effects represent a an offset of impairment
due to marginal deficiencies or an improvement due to sub-
optimal levels that would not, under current guidelines, be
classed as deficiency. However, given that a large section of
the population are unable or unwilling to eat the adequately
balanced diet that would satisfy their micronutrient require-
ments (Scientifc Advisory Committee on Nutrition 2008), it
seems that supplementation with multi-vitamins/minerals
may be a useful and possibly necessary option for this
portion of the population.
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